-
Sep 17, 2024 | 
mdpi.com | Carol Hitchon |Gilles Boire |PAUL FORTIN |Louis Flamand
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Sep 8, 2024 | 
mdpi.com | Olga Tsyruk |Gilaad G. Kaplan |PAUL FORTIN |Carol Hitchon
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Aug 28, 2024 | 
preprints.org | Carol Hitchon |Gilles Boire |PAUL FORTIN |Louis Flamand
PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 27 August 2024 / Approved: 28 August 2024 / Online: 28 August 2024 (10:39:29 CEST)Hitchon, C. A.; Bowdish, D. M. E.; Boire, G.; Fortin, P. R.; Flamand, L.; Chandran, V.; Dayam, R. M.; Gingras, A.-C.; Card, C. M.; Colmegna, I.; Larché, M. J.; Kaplan, G. G.; Lukusa, L.; Lee, J. L.; Bernatsky, S.
-
Aug 5, 2024 | 
preprints.org | Gilaad G. Kaplan |PAUL FORTIN |Carol Hitchon |Olga Tsyruk
PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 2 August 2024 / Approved: 5 August 2024 / Online: 5 August 2024 (11:52:04 CEST)Tsyruk, O.; Kaplan, G. G.; Fortin, P. R.; Hitchon, C. A.; Chandran, V.; Larché, M. J.; Avina-Zubieta, A.; Boire, G.; Colmegna, I.; Lacaille, D.; Lalonde, N.; Proulx, L.; Richards, D. P.; Boivin, N.; DeBow, C.; Kovalova-Wood, L.; Paleczny, D.; Wilhelm, L.; Lukusa, L.; Pereira, D.; Lee, J. L.; Bernatsky, S.
-
Jul 2, 2024 | 
acrjournals.onlinelibrary.wiley.com | Rami Habib |Roya M. Dayam |Carol Hitchon |Vinod Chandran
INTRODUCTION Although we are recovering from the COVID-19 pandemic, SARS-CoV-2 remains a public health threat,1 particularly for those taking immunosuppressants for immune-mediated inflammatory disorders (IMIDs), such as inflammatory bowel disease (IBD), psoriasis (including psoriatic arthritis [PsO/PsA]), rheumatoid arthritis (RA), spondylarthritis (SpA), and systemic lupus erythematosus (SLE).2-5 Serological responses (eg, anti-Spike [S] or anti–receptor binding domain [RBD]) to COVID-19...
-
Jul 1, 2024 | 
jrheum.org | Dawn M.E. Bowdish |Vinod Chandran |Carol Hitchon |Gilaad G. Kaplan
Key Indexing Terms:autoimmune diseasesinflammatory bowel diseasepsoriatic arthritisrheumatic diseasessystemic lupus erythematosusvaccinationSARS-CoV-2 precipitated a global crisis in 2020; unfortunately, this virus has not been eliminated, but is now endemic.
-
May 9, 2024 | 
jrheum.org | Dawn M.E. Bowdish |Vinod Chandran |Carol Hitchon |Gilaad G. Kaplan
When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study Dawn M.E. Bowdish, Vinod Chandran, Carol A. Hitchon, Gilaad G. Kaplan, J. Antonio Avina-Zubieta, Paul R. Fortin, Maggie J. Larché, Gilles Boire, Anne-Claude Gingras, Roya M. Dayam, Ines Colmegna, Luck Lukusa, Jennifer L.F. Lee, Dawn P. Richards, Daniel Pereira, Tania H. Watts, Mark S. Silverberg, Charles N.
-
Apr 10, 2024 | 
jrheum.org | Dawn M.E. Bowdish |Vinod Chandran |Carol Hitchon |Gilaad G. Kaplan
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study Dawn M.E. Bowdish, Vinod Chandran, Carol A. Hitchon, Gilaad G. Kaplan, J. Antonio Avina-Zubieta, Paul R. Fortin, Maggie J. Larché, Gilles Boire, Anne-Claude Gingras, Roya M. Dayam, Ines Colmegna, Luck Lukusa, Jennifer L.F. Lee, Dawn P. Richards, Daniel Pereira, Tania H. Watts, Mark S. Silverberg, Charles N.
-
Jul 1, 2023 | 
jrheum.org | Glen S Hazlewood |Inés Colmegna |Carol Hitchon |PAUL FORTIN
METHODSSurvey design. We designed a DCE to quantify trade-offs relevant to the choice of available COVID-19 vaccines. The DCE was designed as an online survey, using Sawtooth Software (Orem), and followed best practices for the development of DCEs.7 A draft survey was developed by the research team, which included clinicians, researchers, vaccine experts, and patients.
-
May 31, 2023 | 
bmjopen.bmj.com | Carol Hitchon |Christine M. Mesa |Charles Bernstein |Ruth Ann Marrie
ResultsBetween 12 March 2021 and 30 July 2022, we recruited 339 participants (online supplemental figure 2). Vaccination and disease activity data for the time points reported herein were available for 327 participants (78 IA: 77% rheumatoid arthritis; 84 SARDs: 57% lupus; 93 IBD: 43% Crohn’s; and 72 MS: 71% relapsing-remitting) (table 1). Most were female (79.4%) and white (84.7%), with a mean (SD) age of 56.0 (14.3) years.
